Host genetic susceptibility to adult pulmonary Mycobacterium avium complex disease remains unknown. To identify genetic loci for the disease, we prepared 3 sets of pooled DNA samples from 300 patients and 300 sexmatched control subjects and genotyped 19,651 microsatellite markers in a case-control manner. D6S0009i-located in the MICA (major histocompatibility complex class I chain-related A) gene, which encodes a ligand of the NKG2D receptor-had the lowest P value in pooled and individual DNA typing. The A6 allele of the microsatellite was significantly associated with female patients (P<.001), whereas the classical HLA-B and HLA-DRB1 alleles did not show significant association. Functional analysis of allelic expression imbalance revealed that A6-derived messenger RNA was more highly expressed than non-A6-derived messenger RNA in human bronchial epithelial cells. MICA was expressed in bronchiolar epithelium, alveolar macrophages, and granulomatous lesions. These findings suggest that MICA might be one of the immune molecules affecting the pathogenesis of the disease.
Host genetic susceptibility to adult pulmonary Mycobacterium avium complex disease remains unknown. To identify genetic loci for the disease, we prepared 3 sets of pooled DNA samples from 300 patients and 300 sexmatched control subjects and genotyped 19,651 microsatellite markers in a case-control manner. D6S0009i-located in the MICA (major histocompatibility complex class I chain-related A) gene, which encodes a ligand of the NKG2D receptor-had the lowest P value in pooled and individual DNA typing. The A6 allele of the microsatellite was significantly associated with female patients (P<.001), whereas the classical HLA-B and HLA-DRB1 alleles did not show significant association. Functional analysis of allelic expression imbalance revealed that A6-derived messenger RNA was more highly expressed than non-A6-derived messenger RNA in human bronchial epithelial cells. MICA was expressed in bronchiolar epithelium, alveolar macrophages, and granulomatous lesions. These findings suggest that MICA might be one of the immune molecules affecting the pathogenesis of the disease.
Mycobacterium avium complex (MAC) exists in a natural environment, such as water, soil, and dust [1] . MAC infection causes disseminated disease in immmunocompromised hosts but is also known to cause pulmonary disease in individuals without systemic immunosuppression; patients with chronic lung diseases, such as sequelae of tuberculosis and cystic fibrosis, develop the disease, probably because of impaired local defense mechanisms [2, 3] . Apparently healthy middle-aged to elderly women also contract MAC disease with typical granulomatous inflammation and localized bronchiectasis [4 -7] . These lesions often spread and impair pulmonary function. Severe cases are thus fatal, owing to the lack of effective therapeutic measures [4, 8] .
Pulmonary MAC disease is not common. The incidence rate is Ͻ5 cases per 100,000 according to a report from Japan [2] , although detailed epidemiological information is lacking worldwide. Together with possible environmental or bacterial risk factors, these otherwise healthy patients might have genetic susceptibility to the disease. In fact, genetic defects of interferon-␥ or interleukin-12 receptors have been reported to be responsible for the disseminated form of the disease in young pediatric patients [9 -11] , but pathophysiologic analysis in adult sporadic disease has been limited. To date, by analogy with susceptibility to tuberculosis, HLA [12] [13] [14] and natural resistance-associated macrophage protein 1 genes [15] have been investigated, with inconclusive results.
We conducted a multicenter study and collected 300 DNA samples from Japanese patients with pulmonary MAC infection to determine candidate regions in a case-control manner. Unlike recent single-nucleotide polymorphism (SNP)-based genomewide association studies, which have utilized haplotype tag SNPs [16] , the present study started with 3 sequential screenings of pooled DNA samples, which included the typing of 19,651 multiallelic microsatellite markers distributed on the human genome, and ended with individual typing of positive markers. This microsatellite-based approach has already identified candidate susceptibility regions for complex genetic diseases in other studies [17] [18] [19] , and its advantages and drawbacks have also been discussed in detail elsewhere [17] . We conclude that one of the immune-related genes, MICA (major histocompatibility complex class I chain-related A) [20] , might be involved in the development of the mycobacterial infectious disease.
METHODS

Case patients.
A total of 300 unrelated Japanese patients with pulmonary MAC disease were recruited in 2001-2004 at KinkiChuo Chest Medical Center (100 patients), International Medical Center of Japan (97 patients), National Hospital Organization (NHO) Omuta Hospital (58 patients), NHO Tokyo Hospital (25 patients), and NHO Nishi-Niigata Chuo Hospital (20 patients). The average age at onset was 63.4 years, and the male-to-female ratio was ϳ1:3. Pulmonary MAC infection was diagnosed on the basis of the 1997 American Thoracic Society statement [21] ; in brief, all patients had clinical manifestations, small nodules with or without bronchiectasis on computed tomographic images, and bacteriologically definite MAC infection. Patients with or without underlying diseases were enrolled, but those with obviously immunodeficient states (e.g., hematological malignancy, receipt of immunosuppressive therapy, and HIV infection) were excluded. Cultured mycobacterial species were differentiated using a polymerase chain reaction (PCR) kit (Amplicor Mycobacterium tests; Roche Diagnostics). Clinical profiles and backgrounds of all subjects were extracted from medical records and interviews conducted by trained medical staff. Samples from all 300 case patients were randomly divided into 3 sets of 100 samples to enable 3-stage screening.
Control subjects. As controls, 2 panels were prepared, consisting of samples from healthy sex-matched Japanese volunteers from the same area. The first panel, which included 300 samples (control group 1), was further divided into 3 sets of 100 samples, to be used for pooled and subsequent individual typing for screening. The second panel, control group 2, which included 494 samples, was obtained mainly from the Health Science Research Resources Bank (Japan Health Sciences Foundation) and used for further individual genotyping of the positive marker.
Three hundred sex-matched samples randomly selected from control group 2 were also used for the genotyping of classical HLA genes.
Consent/ethics. Written informed consent was obtained from each individual. The present study protocol was approved by the local ethics committees of all participating institutions.
Microsatellite markers, DNA pooling, and typing. We used 19,651 genomewide-designed microsatellite markers, described by Tamiya et al. [17] . Detailed information on microsatellites is available from the Japan Biological Information Research Center (see http://www.jbirc.aist.go.jp/gdbs/). DNA pooling and typing were performed in accordance with the protocol of Tamiya et al. [17] . Each DNA pool contained an equal amount of DNA collected from 100 individual case patients or control subjects. PCR amplification was performed using 96 ng of pooled DNA in a 20-L reaction solution. The microsatellite typing followed standard protocols using the ABI 3700 DNA analyzer (Applied Biosystems). Peak positions and heights of pooled typing were automatically extracted by the Pick Peak (version 1.7) and Multi Peaks programs developed by Applied Biosystems Japan. After pooled DNA typing of case patients and control subjects was performed 3 times sequentially, positive markers were subsequently investigated by individual genotyping and analyzed by GeneScan (version 3.7) and Genotyper (version 2.0) software (Applied Biosystems).
DNA-based typing of HLA-B and HLA-DRB1. DNAbased HLA typing was performed using the Luminex MultiAnalyte Profiling System (xMAP technology) with the WAKFlow HLA Typing Kit (Wakunaga). Polymorphic regions of HLA genes were amplified using primer pairs from the kit. Each PCR product was hybridized with allele-specific oligonucleotide probes.
Detection of a large-scale deletion of the MICA gene and correction of MICA allele frequencies. Large-scale deletion of the human genome is known to cause a null allele of the MICA gene, which was exclusively found in HLA-B*4801-carrying individuals in the Japanese population [22] . In microsatellite analysis, heterozygous samples that have this deletion are misidentified as homozygotes of the corresponding allele. Therefore, our individual typing in the D6S0009i marker located in the MICA gene had to be corrected by the multiplex PCR method reported elsewhere by Komatsu-Wakui et al. [23] when samples from case patients were compared with samples from control group 2; 2 of the primer pairs are located inside boundaries of the large-scale deletion and produce PCR fragments of 180 and 160 bp, respectively, when the deletion does not exist. On the basis of nucleoside sequences specific to the HLA-B*4801-containing haplotypes, the third primer pair was designed outside the deletion and produces a PCR fragment of 880 bp when the deletion exists.
MICA gene allelic expression imbalance. Allele-specific messenger RNA (mRNA) expression by the MICA gene was evaluated in bronchial cells isolated from cancer-free bronchi of the surgically resected lung. Primary cultured bronchial epithelial cells obtained from 42 individuals heterozygous for A6 and non-A6 alleles of D6S0009i marker in the MICA gene were tested for allelic expression imbalance, for which a detection method has been well established in principle [24 -26] . Briefly, one of the coding SNPs in exon 3 of the MICA gene, rs1051790, was used as a marker to distinguish between mRNAs deriving from the A6 allele and those deriving from non-A6 alleles, because the G/C allele of the SNP is in perfect linkage disequilibrium with the A6/non-A6 allele in the Japanese population, according to the IMGT/HLA Sequence Database (http://www.ebi.ac.uk/imgt/ hla/align.html) as well as other reports [22, 27] .
First, 1 g of RNA extracted from human bronchial cells was reverse transcribed into complementary DNA (cDNA) using Superscript III reverse transcriptase (Invitrogen) in a 20-L reaction. For PCR amplification, 2 L of cDNA was used with AmpliTaq Gold DNA polymerase (Applied Biosystems). Nucleotide sequences of the primer set were 5'-ACCAGGGACTTGAC-AGGGAACGGAA-3' (forward) and 5'-ATGGGGGGCACTG-TTCTCCTCAGGA-3' (reverse). Either of the primers was labeled with fluorescent dye, 6-carboxyfluorescein (Applied Biosystems), to assess the proportion of the corresponding single-stranded fragments. An initial denaturation process at 95°C for 9 min was followed by 35 cycles of 95°C for 15 s, 60°C for 15 s, and 72°C for 30 s and then followed by a final step at 72°C for 7 min. For single-strand conformation polymorphism analysis to separate the 2 alleles, reverse-transcription PCR products were diluted 1:7 in deionized formamide buffer, denatured for 2 min at 94°C, quenched on ice, and loaded onto a glycerol-free 10% polyacrylamide gel. Electorophoresis was done for 3.5 h at 10°C at a constant voltage of 300 V/gel. The relative expression of allele-specific mRNA was quantified on the basis of the difference in band intensities, using the Molecular Imager FX System (Bio-Rad Laboratories) and analysis software (Quantity One 1-D; version 4.5; Bio-Rad Laboratories).
The accuracy of the fluorescence intensity ratio of the PCR products was evaluated in comparison with A6/non-A6 copy numbers of the PCR template: cDNAs of A6 and non-A6 (A9) homozygotes were amplified, respectively, with outer PCR primers MICAoutS (5'-GGGCAGAAGATGTCCTGGGAAA-TA-3') and MICAoutAS (5'-GACATCCCCCCACTGCTGG-GTGTC-3') and cloned into the pCRII-TOPO vector using TOPO TA Cloning Kit Dual Promoter (Invitrogen). A6 and non-A6 plasmid DNAs were isolated by the Qiagen Plasmid Mini Kit (Qiagen), their concentrations were adjusted to 100,000 copies/L and mixed at various ratios, and then 2 L of the mixed DNA was subjected to PCR with fluorescence primers, as described above.
Immunohistochemistry. Surgical lung sections were obtained from formalin-fixed paraffin-embedded tissues affected by pulmonary MAC disease (n ϭ 6) and from apparently normal tissues completely distinct from cancer lesions (n ϭ 3). Surgical sections of colon cancer (n ϭ 6) were also prepared as positive controls in which MICA is strongly manifest. After deparaffinization, tissue sections were rehydrated and treated with 1 mmol/L EDTA (pH 8.0) at 95°C for 30 min in an autoclave for antigen retrieval. To detect MICA expression in the tissue, anti-MICA goat polyclonal antibody was applied (2.5 g/L; raised against recombinant human MICA extracellular domain; R&D Systems). The equivalent amount of goat immunoglobulin (Ig) G (Immuno-Biological Laboratories) was used as a negative antibody control. After overnight incubation at 4°C, endogenous peroxidase activity was blocked by 0.3% H 2 O 2 , and the secondary antibody labeled with peroxidase (Histofine Simplestain MAX PO; Nichirei) was added. MICA expression was visualized by use of 3-amino-9-ethyl-carbazole liquid substrate chromogen (Dako), followed by counterstaining with hematoxylin.
Statistical analysis. To calculate P values for the screening of pooled samples, we used Fisher's exact test with 2 ϫ 2 contingency tables for each allele and the 2 ϫ m contingency table for each locus, where m refers to the number of marker alleles observed in a population. Markers for which P Ͻ .05 were selected as positive at each stage. Allele frequencies in pooled typing were estimated from the heights of peaks. For individual typing, the 2 test was used. Haplotypes were estimated by the expectation-maximization method of the Arlequin program (version 3.1; http://lgb.unige.ch/arlequin) and analyzed by the Haploview permutation method (version 3.2; http://www .broad.mit.edu/mpg/haploview/). The 1-sample t test was done using JMP statistical discovery software (version 5.0.1; SAS Institute) to assess allelic expression imbalance after logarithmic transformation, comparing observed ratios of allele-specific fluorescence intensity with the expected 1:1 ratio (the null hypothesis).
RESULTS
Genomewide screening for a susceptibility gene for pulmonary MAC disease. Three sets of DNA pools were subjected to genomic screening sequentially. At each stage, microsatellite markers were selected when their P values, determined by Fisher's exact test for 2 ϫ 2 or 2 ϫ m contingency tables, were Ͻ.05. In the first stage, 1296 of 19,651 microsatellites were selected. In the second stage, 263 of the 1296 microsatellites were further extracted. After 3-stage genomewide screening, 42 microsatellites remained. Subsequent individual genotyping further excluded false-positive markers mainly attributable to experimental artifacts in the pooled DNA typing. Eventually, 4 of the 42 microsatellites met the selection criterion; that is, the uncorrected P value of a single allele was Ͻ.05 in both pooled and individual typing (table 1) .
Of the 4 markers, D6S0009i showed the best values (P Ͻ .001; odds ratio, 1.53 [95% confidence interval, 1.19 -1.96]) when all 300 case samples were compared with 300 control samples (con-trol group 1). Indeed, this microsatellite marker was located in the MICA gene in the HLA region and is known as the MICA-TM polymorphism [28] . Within 100-kb regions upstream and downstream of D11S0536i or D13S791, no genes were identified. D17S1290 was located near the eosinophil peroxidase and lactoperoxidase genes. Because a relationship between gene function and the underlying pathophysiology is not expected at the present time, further analysis of these genes was not considered in the present study.
Allele frequencies of MICA-TM in patients with MAC and another set of control subjects. To address a disease susceptibility gene, we thus selected MICA-TM as a most likely candidate and further compared 300 samples from case patients with another control set of DNA samples (control group 2) by individual typing. We subsequently detected null alleles of MICA and discovered 25 null alleles in control subjects and 10 in the case patients. Even after this correction, the A6 allele was more frequent in the case patients (P ϭ .048) (table 2). When only female subjects were included, the association was more robust (P Ͻ .001) (table 3). In the male subgroup, consisting of 74 patients, a significant association was not observed (data not shown).
HLA-B and HLA-DRB1 genotyping. Association with the
HLA-B gene was tested because of strong linkage disequilibrium with the MICA gene [22, 23] . The HLA-DRB1 gene was also analyzed because of a reported association with mycobacterial diseases, including MAC disease [12, 13, 29 -31] . All 300 case patient and 300 sex-matched control samples randomly chosen from control group 2 were compared. HLA-B and HLA-DRB1 alleles did not show significant association with MAC disease (data not shown). Even when samples from female patients were compared with those from female control subjects, corrected P values did not reach significant levels when multiplied by the number of alleles (table 4), whereas the association with the A6 allele of MICA-TM remained significant (corrected P ϭ .028) (data not shown). HLA haplotypes were further analyzed, and 2 major haplotypes carrying the A6 allele, B*5201-A6-DRB1*1502 and B*4403-A6-DRB1*1302, were estimated, but these haplotypes were not associated with the disease according to the permutation test (data not shown).
MICA gene allelic expression imbalance. To determine whether the amount of MICA gene expression differs between A6 and non-A6 alleles, allele-specific mRNA expression of the MICA gene was evaluated in human cells heterozygous for A6 and non-A6 alleles. This is a method to measure relative amounts of mRNA generated from each of the 2 alleles within each subject, using a genetic marker in the transcribed region of the gene. Allelic expression ratios are considered to represent a more robust phenotypic marker than absolute mRNA levels, which fluctuate between subjects with changes in cellular environment or trans-acting factors [24 -26] . First, the validity of the allele-specific ratio in this system was evaluated by measuring the fluorescence intensity of PCR products derived from a mixture of A6 and non-A6 templates at known ratios. The proportion of fluorescence intensity indicating A6-specific expression showed good correlation with the original proportion of A6-derived template when forward or reverse primer was labeled with fluorescent dye (r 2 ϭ 0.9927 and r 2 ϭ 0.9803, respectively). Next, the fluorescence intensity of reverse-transcription PCR products from human primary cultured bronchial epithelial cells was measured. The expression ratio of A6 to non-A6 mRNA was 1.6, on average, and the distribution of the ratio after logarithmic transformation was significantly higher than 0, assuming no imbalance between A6-derived and non-A6-derived mRNA expression (figure 1A) (P Ͻ .001). The proportion measured by a fluorescence primer bound to the other strand showed similar results (figure 1B) (P ϭ .008). These results indicate that the A6 allele is associated with elevated MICA mRNA expression levels.
Immunohistochemistry for MICA. Human tissue sections were stained with anti-MICA antibodies. A strong signal was shown in all tested samples from patients with colon cancer, as has been reported by others [32] (figure 2A and 2B ). In the apparently normal lung sections, positive staining was observed in bronchiolar epithelium and alveolar macrophages ( figure 2C and 2D) . In addition to the above-described staining, in the lung sections from patients with pulmonary MAC disease, epithelioid cells and multinucleated giant cells composing granuloma were clearly stained with the anti-MICA antibodies ( figure 2E and 2F) .
DISCUSSION
We conducted a case-control association study of pulmonary MAC disease, using polymorphic markers distributed genomewide, and we identified MICA polymorphism as a susceptible variation. Subsequent gene expression analysis showed localization of MICA and possible significance of the allele in the lungs. Thus, MICA was found to be one of the promising molecules in pulmonary MAC disease.
With this microsatellite-based approach, Tamiya et al. [17] first showed new susceptible regions for rheumatoid arthritis, and then similar study designs were successfully used to investigate narcolepsy and hypertension [18, 19] . Recently, SNP-based genomewide association analysis achieved very promising results [16, 33] , but such a platform was not available when we started the present study. The use of pooled DNA has been discussed as a cost-effective approach with minimal biases and errors when the study is well designed and putative associations are confirmed by individual typing [34] .
The reproducibility of our results should be investigated in the future, as in other association studies, because of the following limitations. The P values shown by D6S0009i through this analysis are not robust enough when multiple comparisons are taken into account, although Bonferroni's correction might be too conservative to detect associations between multiple marker loci and a complex genetic disease, as has been often discussed elsewhere [35] . We also note that the power to detect risk variants is low with this design, when relative risk is as low as that of the variant (odds ratio, 1.5) identified in this study. Nevertheless, it is noteworthy that MICA is a key molecule in human innate immunity, and the best positive marker within the gene was Figure 1 . Expression imbalance between A6 and non-A6 alleles. The ratio of A6 to non-A6 expression after logarithmic transformation is shown in the bronchial epithelial cells of 42 heterozygotes. The forward (A) and reverse (B) primers were labeled with fluorescent dye. The ratio of A6 to non-A6 expression was significantly higher than the expected value of 0, assuming no imbalance after logarithmic transformation by 1-sample t test (P Ͻ .001 for panel A and P ϭ .008 for panel B; 1-sample t test).
identified in a larger sample than in other studies of pulmonary MAC disease [12] [13] [14] [15] .
In addition, female patients showed a stronger association than did patients of both sexes combined and might be more affected by the combination of host genetic factors, including the MICA gene, and putative sex-specific factors, such as hormonal change, which is presumably involved in the female predominance of this disease [4 -7, 36] . The number of male patients was rather small and did not provide enough power to detect similar risk in this subgroup.
As reported elsewhere, HLA-B and MICA are in strong linkage disequilibrium, and MICA-A6 composes haplotypes with HLA-B*5201, 4403, and 5101. HLA-DRB1 loci, especially DR2 (DRB1*15) and DR6 (DRB1*13 or *14), have been shown elsewhere to be associated with MAC and other mycobacterial diseases in studies with relatively small samples [12, 14, 29 -31] . In our present study, however, disease association with HLA-B and HLA-DRB1 alleles did not reach significant levels, whereas A6 showed a significant association with the disease in the same sample set. Linkage disequilibrium around major A6-containing haplotypes, such as B*5201-A6-DRB1*1502, may explain simply why other studies have shown disease association with classical HLA genes [29 -31] . Thus, MICA should also be considered when HLA alleles are associated with mycobacterial diseases. MICA is functionally known as one of the ligands to engage the NKG2D receptor on natural killer cells, ␥-␦ T cells, and CD8 T cells. This molecule is a stress-induced, membrane-bound glycoprotein that is expressed in intestinal epithelium and other tissues [37] [38] [39] . A recent report showed that MICA is also expressed in human bronchial epithelium [40] . In association studies, frequencies of the A6 allele and HLA-B51 in Behçet's disease [41, 42] and A6 and HLA-B52 in ulcerative colitis [43] are significantly higher than in control populations. In our study, as in others, the A6 allele showed positive association with the disease. The null allele or A5.1 allele, which may impair MICA function, was not associated with the disease, presumably because of functional compensation by other human NKG2D ligands [44] .
Our experiment with allelic expression imbalance demonstrated that the constitutive expression of the MICA gene in bronchial epithelial cells is genetically determined, at least in part, and that the A6 allele acts as a marker of high MICA expression, although the primary significance of alanine repeats in the transmembraneous region of MICA-TM polymorphism remains unclear. Possible roles of other unknown polymorphisms in linkage disequilibrium with the A6 allele should also be investigated in the future.
MICA was detected by immunohistochemical analysis in alveolar macrophages, epithelioid cells, and multinucleated giant cells in granulomatous lesions of MAC disease as well as in bronchiolar epithelium. This is not surprising, because recent reports have shown that MICA is expressed in the monocytemacrophage lineage as well as in epithelial cells [45] [46] [47] . Local macrophages are known to play a critical role in immunity to intracellular pathogens, such as mycobacterial species [48] . These findings imply that the A6 allele or A6 haplotypes might generally provoke inflammatory response or tissue damage, which might be the case with pulmonary mycobacterial diseases, at least in part, although the effect of MICA itself might be relatively weak. Future genetic analysis of other functionally equivalent NKG2D ligands, such as members of the UL-16 binding protein family, might provide an answer concerning this hypothesis [44] . In conclusion, using a genomewide case-control approach and subsequent functional analysis of gene expression, we found that MICA is one of the promising candidate molecules that might be involved in susceptibility to pulmonary MAC disease.
